Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors.
Several biochemical parameters quantitated in tumor cytosols from malignant breast tumors have been evaluated as possible prognostic factors. Cytosol protein content has always been regarded as a reference parameter, to correct for cellularity and representativity of tumor samples. But recent studies have suggested an altered protein distribution in malignant tissues. The present study on 382 women with histologically proven breast cancer, Stage I and Stage II, therefore evaluates whether cytosol protein content by itself may add information as a prognostic factor in the clinical management of breast cancer. Cytosol protein content was found to be significantly correlated (p less than 0.001) to tumor size, and inversely correlated to progesterone receptor (PgR) content (p = 0.015) and age at operation (p = 0.021). Using the median value of protein (4.15 mg/ml) as a cut-off value, two groups could be constructed. The number of node-positive patients in the protein-poor group was significantly decreased (p = 0.018) compared to the protein-rich group, which also contained a significantly (p less than 0.001) lower number of patients with estrogen receptor (ER) positive tumors (i.e. ER greater than or equal to 10 pmol/g). An increased number of events was observed in the protein-rich group (p less than 0.001), with a great contribution to the number of deaths due to breast cancer. In a multivariate analysis of the likelihood to predict axillary nodal involvement, protein category was found to be a significant (p less than 0.031) independent predictive factor. As to relapse free survival (RFS), protein category did not reveal any prognostic power.(ABSTRACT TRUNCATED AT 250 WORDS)
Søreide
J A
JA
Dept. of Surgery, Rogaland Central Hospital, Stavanger, Norway.
Lea
O A
OA
Kvinnsland
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D003600:Cytosol / Q000737:chemistry*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone